Methotrimeprazine-Associated Stevens-Johnson Syndrome in 2 Ashkenazi Jewish Patients

Moubayed, Dina; Gifuni, Anthony J.; Tourian, Leon

doi:10.1097/jcp.0000000000000641

Cited by 5 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A possible association of SJS/TEN with the tyrosine kinase inhibitor cabozantinib is reported here for the first time. Interestingly, levomepromazine (named also methotrimeprazine)-associated SJS we describe had been reported only in two Ashkenazi Jewish patients in Canada [33], thus providing a clue for a probable genetic factor that might play a role in risk. A case of TEN in a patient with COVID-19, which was assessed as probably related to hydroxychloroquine, has been recently published [34].…”

Section: Discussionmentioning

confidence: 83%

Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study

et al. 2022

View full text Add to dashboard Cite

Objective Our objective was to describe the incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in a large unselected cohort, to validate the culprit drugs involved and the frequency of SJS/TEN for each drug, and to analyze the clinical risk factors for SJS/TEN. Methods Using the computerized database of Clalit Health Services, we identified all adult patients with a new SJS/TEN diagnosis between 1 January, 2008 and 30 June, 2019 and validated each case. Cumulative incidence of SJS/TEN for each culprit drug was calculated by dividing the number of valid cases by the total number of new users of the drug in the study period. Using risk-set sampling, 20 controls were matched to each case by sex and age on the index date for a nested casecontrol analysis. Multivariable conditional logistic regression was used to estimate the odds ratio and 95% confidence interval for the association of incident SJS/TEN with chronic diseases. Results We identified 87 adult cases of true/probable SJS/TEN between 1 January, 2008 and 30 June, 2019. Culprit drugs [with ALDEN scores ascertained as at least probable (≥ 4)] associated with the highest absolute risks were phenytoin, lamotrigine, and allopurinol with 3.56, 2.82, and 1.10 SJS/TEN cases/10,000 new users, respectively. Additional drugs with mean ALDEN scores ≥ 4 were sunitinib, sulfasalazine, carbamazepine, etoricoxib, etodolac, and cefuroxime, cumulative incidence: 13.57, 0.72, 0.32, 0.05, 0.02, and 0.02/10,000 new users, respectively. Previous diagnosis of systemic lupus erythematosus, psoriasis, previous drug allergies, epilepsy, malignancy, history of cerebrovascular accident, and history of diabetes mellitus were associated with an increased risk for SJS/TEN, odds ratios (

show abstract

Section: Discussionmentioning

confidence: 83%

Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…(Yang et al, 2019;Zhao et al, 2019). Some rare cases are caused by less commonly seen drugs like albuterol (Maggini et al, 2015;Shariff et al, 2017), taurine-containing energy drink (Begolli Gerqari et al, 2016), radiotherapy for cancers (Rouyer et al, 2018;Esaa et al, 2020), fertility treatment (Hashimoto et al, 2019), vaccines (Oda et al, 2017;Chahal et al, 2018;Flora et al, 2018;Su et al, 2020), commercial cannabinoid oil (Yin et al, 2020), herbs (Bonhomme et al, 2017;Lim et al, 2018), teriflunomide (treating multiple sclerosis) (Gerschenfeld et al, 2015), methotrimeprazine (Moubayed et al, 2017), diuretic drug metolazone (Kumar et al, 2016), etoricoxib (Roy et al, 2018), Dalbergia cochinchinensis (a tree) (Yang et al, 2015), etc. Anticancer drugs like protein kinase inhibitors ribociclib (Lopez-Gomez et al, 2019), palbociclib (Karagounis et al, 2018), afatinib (Doesch et al, 2016), and vemurafenib (Arenbergerova et al, 2017), immune checkpoint inhibitors (ICIs) (including cytotoxic T lymphocyte associated antigen-4 [CTLA-4: monoclonal antibody ipilimumab (Dika et al, 2017)], programmed cell death protein [PD-1: monoclonal antibody nivolumab (Nayar et al, 2016;Salati et al, 2018;Dasanu, 2019), pembrolizumab (Lomax et al, 2019)], programmed cell death ligand 1 [PD-L1: monoclonal antibody atezolizumab (Chirasuthat and Chayavichitsilp, 2018)], and CC chemokine receptor 4 targeting antibody mogamulizumab (Tanba et al, 2016) are also reported to cause SJS/TEN.…”

Section: Introductionmentioning

confidence: 99%

Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Cheng

2021

Front. Pharmacol.

View full text Add to dashboard Cite

Adverse drug reactions are a public health issue that draws widespread attention, especially for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) which have high mortality and lack of efficacious treatment. Though T-cell-mediated HLA-interacted immune response has been extensively studied, our understanding of the mechanism is far from satisfactory. This review summarizes infection (virus, bacterial, and mycoplasma infection), an environmental risk factor, as a trigger for SJS/TEN. The mutations or polymorphisms of drug metabolic enzymes, transporters, receptors, the immune system genes, and T-cell-mediated apoptosis signaling pathways that contribute to SJS/TEN are discussed and summarized. Epigenetics, metabolites, and mobilization of regulatory T cells and tolerogenic myeloid precursors are emerged directions to study SJS/TEN. Ex vivo lymphocyte transformation test has been exploited to aid in identifying the causative drugs. Critical questions on the pathogenesis of SJS/TEN underlying gene polymorphisms and T cell cytotoxicity remain: why some of the patients carrying the risky genes tolerate the drug and do not develop SJS/TEN? What makes the skin and mucous membrane so special to be targeted? Do they relate to skin/mucous expression of transporters? What is the common machinery underlying different HLA-B alleles associated with SJS/TEN and common metabolites?

show abstract

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case–Control Study

et al. 2018

View full text Add to dashboard Cite

show abstract

Methotrimeprazine-Associated Stevens-Johnson Syndrome in 2 Ashkenazi Jewish Patients

Cited by 5 publications

References 10 publications

Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study

Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study

Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case–Control Study

Contact Info

Product

Resources

About